http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 08:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html <p>Arcus Biosciences (NYSE: RCUS) announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate casdatifan in combination with an investigational cancer treatment for advanced renal cell carcinoma.</p> <p>Under the agreement, Arcus will supply casdatifan, its investigational HIF-2a inhibitor, for inclusion in Bristol Myers Squibb's Phase 1/2 ROSETTA RCC-208 clinical trial. The trial will evaluate pumitamig, a PD-L1/VEGF-A bispecific antibody being jointly developed by BioNTech and Bristol Myers Squibb, alone or in combination with other treatments for advanced kidney cancer.</p> <p>The collaboration will add two new treatment arms to the existing trial featuring casdatifan combinations. Each company http://www.streetinsider.com/Corporate+News/Arcus+Biosciences+partners+with+Bristol+Myers+Squibb+on+kidney+cancer+trial/26595693.html Wed, 03 Jun 2026 08:01:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Press+Releases/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html <ul class="bwlistdisc"> <li> <i>This collaboration aims to develop a novel treatment regimen that delivers more sustained tumor control in kidney cancer, a cancer of high unmet medical need</i> </li> </ul> <p> HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced a clinical trial collaboration and supply agreement with Bristol Myers Squibb (NYSE: BMY, “BMS”). Under the agreement, Arcus will supply casdatifan, the company’s investigational small-molecule HIF-2a inhibitor, to be evaluated as part of the BMS-sponsored Phase 1/2 ROSETTA RCC-208 clinical http://www.streetinsider.com/Business+Wire/Arcus+Biosciences+Announces+Clinical+Trial+Collaboration+and+Supply+Agreement+to+Evaluate+Casdatifan+in+Combination+with+PD%E2%80%91L1VEGF%E2%80%91A+Bispecific+Immunomodulator+to+Treat+Kidney+Cancer/26595588.html Wed, 03 Jun 2026 08:00:00 -0400 0A3M A.22847412 BMS BMY O.00000283 O.03960636 O.07073414 O.29486884 RCUS